Combining Gilead's (GILD) sofosbuvir and Bristol-Myers Squibb's (BMY) daclatasvir cures 100% of...

Combining Gilead's (GILD) sofosbuvir and Bristol-Myers Squibb's (BMY) daclatasvir cures 100% of hepatitis C patients in 12 weeks (including those who failed treatment with Vertex's (VRTX) Incivek and Merck's (MRK) Victrelis) and looks to be a better treatment option for those with genotype 3 than a combo of sofosbuvir and another GILD drug ledipasvir. The problem: "GILD very clearly wants to develop in-house," one clinician tells Bloomberg. (See also: ABBV's HCV treatment successful;  VRTX teams with BMY on HCV trial)

From other sites
Comments (5)
  • drtolis
    , contributor
    Comments (2) | Send Message
    I am 53 years old with HCV genotype 4 ; failed treatment with interferon + ribavirin with me .
    When this new drug will be in the market ?
    28 Apr 2013, 02:34 PM Reply Like
  • Rootarmo
    , contributor
    Comments (373) | Send Message
    You realistically looking at Q2 of 2014...Gilead's drug was Just ..and by Just we are talking about 2 weeks ago submitted for approval with the FDA.


    The one thing I am not certain is whether genotype 4 is part of what it was submitted for approval.
    28 Apr 2013, 06:43 PM Reply Like
  • tcarilli
    , contributor
    Comment (1) | Send Message
    I am a post liver transplant patient with genotype 1 hep C.Will it help my case?
    29 Apr 2013, 01:40 AM Reply Like
  • JohnnyHorses
    , contributor
    Comment (1) | Send Message
    You need to get into a trial with sofosbuvir a.s.a.p.!!! You are post-transplant, with genotype 1 hep C. You cannot wait. Do not wait for your doctor if he/she is telling you to wait/be patient! Not meaning to scare you but you do not have that luxury.
    14 May 2013, 12:12 AM Reply Like
  • Rootarmo
    , contributor
    Comments (373) | Send Message
    The direct-acting agent is intended for use as a once-daily, all-oral therapy among patients with chronic HCV genotypes 2 and 3, and also as combination therapy with pegylated interferon and ribavirin among those with genotypes 1, 4, 5 and 6. However even with interferon the cycle to make the virus non-detectable in the blood will be cut in half from what is going on now.


    The plan is eventually to offer an all-oral therapy for all the genotypes but that is still a while away since the second part of the cocktail from Gilead have not been submitted for approval.


    They have done this with HIV..eventually work their way where you take one single pill. While the the wait can be grueling ..what it looks like is the light is at the end of the tunnel for tolerable treatment.
    29 Apr 2013, 12:12 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs